Although sporadic and rare, human H5N1 infections cause rapid dissemination of virus to multiple organs and are associated with severe disease and high mortality [1] . The current therapeutic regimen for H5N1 influenza mainly relies on antiviral drugs [2] . However, resistance to the ion-channel blockers amantadine and rimantadine has been identified in some H5N1 isolates [3] , and although neuraminidase inhibitors such as oseltamivir and zanamivir are effective for treatment of seasonal influenza A in humans, they demonstrate efficacy against H5N1 infection in animal models only when administered before or soon after infection [4 -6] and are less clearly effective in the treatment of H5N1 infections in humans [1, 2] . Difficulties in treatment and high mortality rates may be attributable to failures in identifying infection in the initial phase and, once the virus is detected, to a lack of effective treatments for inhibiting virus spread within the body. Alternative treatments to rapidly neutralize and control dissemination of H5N1 virus in humans after symptoms emerge are being actively explored. Passive immunotherapy has been used increasingly in the treatment of infectious diseases [7] , and treatment with convalescent-phase blood and serum products was found to result in distinct improvement of clinical outcomes in severely ill influenza pa-tients during the 1918 influenza pandemic, as well as in a more recent case of H5N1 infection in a person [8, 9] . In animal experiments, passive immunization with either H5-specific hyperimmune serum or monoclonal antibodies (MAbs) has proved highly effective in protecting against H5N1 infection [10 -12] . However, to achieve neutralization, therapeutic antibodies rely on specific binding to epitopes in the hemagglutinin (HA) protein of influenza viruses. Continuous evolution and cocirculation of multiple genetic H5N1 lineages in broad regions have, however, generated antigenically diverse variants that pose significant challenges for developing broadly cross-protective therapeutic MAbs [13, 14] .
We recently demonstrated that there are at least 4 major antigenic groups of H5N1 viruses currently in circulation; all have caused infection in humans [15] . The recent emergence and development of the unique antigenic FJ-like virus (clade 2.3.4) in Asia [14, 16, 17] , the continuous circulation and expansion of Qinghai-like virus (clade 2.2) in Europe, the Middle East, and Africa [18 -21] , and the persistent prevalence of clade 2.1 viruses in Indonesia [22, 23] all suggest that, with time, more antigenicdrift variants will arise. This poses a great challenge for generating broadly cross-protective MAbs against H5N1 infection. Here, we describe a panel of H5-specific MAbs derived using H5N1 strains representing most of the genetic clades. Fifty-two broadly cross-reactive MAbs were selected using hemagglutination inhibition and cell-based neutralization assays. The properties of these MAbs were characterized, and their value in protecting against infection with various antigenically distinct H5N1 strains was confirmed in animal experiments. Our data suggest that some of these MAbs may prove valuable for controlling future infections by variant viruses.
MATERIALS AND METHODS
Virus. H5N1 viruses used in this study were selected from different phylogenetic clades/subclades and grown in 10-day-old specific pathogen-free embryonated chicken eggs at 35°C for 30 h. Allantoic fluids were harvested and kept at Ϫ80°C until use. The virus titer was determined by infection of MDCK cells and was expressed as the 50% tissue culture infectious dose (TCID 50 ) per milliliter, in accordance with the method of Reed and Muench [24] . For mouse immunization, viruses were inactivated by adding formalin to a final concentration of 0.03% and were incubated at 4°C for 72 h, after which allantoic fluids were tested to confirm inactivation. All experiments involving live virus were conducted in a BSL-3-enhanced containment facility at the University of Hong Kong.
Generation of H5 MAbs. Five representative H5N1 strains were chosen as immunogens from these major genetic clades/ subclades on the basis of phylogenetic analysis. Preparation of anti-H5 MAbs followed standard hybridoma technology, as previously described [25] . Six-week-old female BALB/c mice were injected subcutaneously with 5 ϫ 10 7 TCID 50 /mL of formalininactivated A/Ck/HK/YU22/2002 (clade 8) [26] . Fusion was performed 6 weeks after the final immunization. The resulting hybridomas were screened for the secretion of H5-specific MAbs against Ck/HK/YU22/2002 and other non-H5 reference viruses, using a hemagglutination inhibition assay. Cells that produced MAbs were cloned by means of a limiting dilution at least 3 times, and MAb-positive clones were expanded and cultured in 75-cm 2 flasks. MAbs were prepared by injecting hybridoma cells into the peritoneal cavities of pristane-primed BALB/c mice; ascitic fluid was collected after 9 -12 days and stored at Ϫ20°C.
Hemagglutination inhibition and microneutralization tests. Hemagglutination inhibition was performed to screen for H5-specific MAbs and to assess antibody reactivity against different H5N1 isolates, in accordance with the World Health Organization Manual on Animal Influenza Diagnosis and Surveillance, modified as previously described [15, 27] . Cell-based microneutralization assays were performed as previously described [28, 29] .
Cross-protection by H5-specific MAb. Groups of 6 BALB/c mice aged 6 -8 weeks were anesthetized with isoflurane and were inoculated intranasally with 10 times the 50% mouse lethal dose To determine the dose response, mice challenged with 10 MLD 50 of the BH Goose/QH/15C/05 strain received 13D4 in doses of 1 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg, 40 mg/kg, and 80 mg/kg. Animals were observed daily for mortality and morbidity, and body weight was measured for up to 14 days after infection. Lung, heart, and brain tissues were collected for virus titration and/or immunohistochemistry analysis at 24-h, 48-h, and 72-h time points.
Virus titration. Whole-lung tissue specimens were collected and stored at Ϫ80°C until use. One lobe of lung tissue from each mouse was homogenized in PBS/antibiotic medium, using sterile acid-washed and calcined sea sand as an abrasive agent. Clarified homogenates were titrated for viral infectivity on MDCK cells. Viral titers were expressed as mean log 10 TCID 50 per gram of lung tissue specimen.
Immunohistochemical analysis. Expression of influenza A nucleoprotein in tissues was examined by immunohistochemical staining of histological sections. In brief, sections were blocked with 1% bovine serum albumin/PBS, stained with an anti-influenza nucleoprotein MAb (clone 17H4, raised against the H5N1 strain A/Ck/HK/YU22/2002) at a dilution of 1:5000 overnight at 4°C, and incubated with goat anti-mouse IgG Hand L-chain-specific biotin conjugate (Calbiochem) at a dilution of 1:2000 for 30 min at room temperature. Tissue sections were then incubated with streptavidin/peroxidase complex reagent (Vector Laboratories) for 30 min at room temperature, and color was developed using 3,3'-diaminobenzidine (Vector Laboratories) according to the manufacturer's instructions.
Selection of escape mutants. The first generation of escape mutants were selected as previously described, with minor modifications [30] . In brief, 1000 times the 50% egg infectious dose (EID 50 ) of virus was mixed with serially diluted 13D4 MAb and incubated at room temperature for 30 min. The mixture was inoculated into 10-day-old embryonated chicken eggs and incubated at 35°C for 48 h. Virus was harvested and subjected to 2 further cycles of selection, and escape mutants were plaque purified. In brief, mutant virus was serially diluted and used to infect MDCK cell layers. Infected cells were overlaid with 1% agarose in MEM medium and were incubated at 37°C in the presence of 5% CO 2 for 2-3 days until plaques appeared. Plaques representing single virus clones were picked and virus expanded in MDCK cells. Escape mutant viruses were subjected to 2 subsequent rounds of plaque purification, and HA gene mutations were then identified by sequencing.
RESULTS

Generation of broad-spectrum H5-reactive MAbs.
In Asia, avian influenza H5N1 virus has become endemic in poultry, and multiple genetic sublineages have been observed since at least 2002 [13, 31] . These genetic clades and subclades include those first observed before the reemergence of infection in humans in Hong Kong during 2003 (i.e., clade 1) and those whose members have caused infection in humans in 15 countries since 2004 (i.e., subclades 2.1-2.3) [26] . A large panel of H5-reactive MAbs were generated by immunizing BALB/c mice first with a clade 8 virus, Ck/HK/YU22/2002, which represents early genetic lineages of H5N1 virus from the first wave of outbreaks across Southeast Asia [32] , followed in succession by 4 other antigenically distinct viruses belonging to clades 1, 2.1, 2.2, and 2.3. From these MAbs, 52 broad-spectrum H5-reactive antibodies were identified and characterized by hemagglutination inhibition against strains from 1997 and other major clades prevalent since 2002 (table 1) . It is suggested that current highly pathogenic avian H5N1 viruses originated from Gs/GD/1996, whose immediate descendants caused the outbreak in Hong Kong in 1997 [33] . Longterm endemicity of H5N1 virus in poultry has led to the establishment of multiple genetic lineages/clades in Asia since then [13, 23, 32] . The observed cross-reactivity with both 1997 ancestral strains and more-recent genetic variants of H5N1 virus implies that these broadly cross-reactive MAbs may target conserved antigenic epitopes in the HA protein of H5N1 virus. The cross-reactive spectrum of these H5 antibodies, as determined by hemagglutination inhibition, was found to correlate with their reactivity in cell-based neutralization assays [15] , suggesting that they were broadly cross-reactive neutralizing antibodies. Taken together, the immunization strategy used in this study succeeded in producing broadly reactive H5 antibodies associated with antigenic specificity that has been conserved since 1997.
Protection against H5N1 infection by H5 MAbs. Because H5N1 virus exhibits highly diversified antigenicity [15] , a comprehensive evaluation of cross-protection for all current major H5N1 antigenic variants is demanded. In this study, 2 broadly cross-reactive MAbs, 13D4 and 8G9, were tested for their ability to protect mice against infection by clade 1, 2.1, 2.2, and 2.3 H5N1 viruses. Groups of 6 mice were challenged intranasally with 10 MLD 50 of virus; our experiments have shown that, without intervention, this dose kills all animals within 7-10 days. Animals typically exhibited weight loss from 2 days after virus challenge until the time of death (figure 1A). Examination of infected animals showed that weight loss was accompanied by spread of the infection from the lung to other organs on day 2 after infection (figure 1B). Treatment with 20 mg/kg of 13D4 (or 8G9; data not shown) provided protection against lethal challenge with 4 H5N1 strains representing clades 1, 2.1, 2.2, and 2.3 (figure 2). Mice rapidly recovered and gained weight, and protection was observed even when treatment was delayed to 2 or 3 days after infection, suggesting that intervention with these MAbs is protective even after virus has disseminated beyond the pulmonary system (figures 1A and 2). The 4 H5N1 strains tested represent current major antigenic groups of H5N1 virus; the broadly cross-reactive MAbs raised in this study appeared to be highly protective against infection with these antigenically diverse H5N1 viruses.
Previous reports of postmortem examinations of humans and animal models of experimentally induced infection indicated that H5N1 virus is able to disseminate to multiple organs soon after infection [34, 35] . To understand the mechanism of 13D4 protection against H5N1 virus infection in mice, we examined the replication kinetics of H5N1 strain A/BH Goose/QH/15C/ 2005 in lung tissue after 13D4 intervention. The virus replicated actively in the lung, reaching its highest level 48 h after infection (figure 3A). After 13D4 treatment, complete neutralization of virus was observed in lung tissues of infected mice within 24 -48 h ( figure 3B) . 13D4 thus appears to act as a highly potent neutralizing antibody for H5N1 virus in vivo, suppressing and neutralizing actively replicating H5N1 virus within a short interval.
MAb-mediated protection against lethal H5N1 challenge is dose dependent. In a separate dose-escalation experiment, protection by 13D4 was shown to vary with dose (table 2). The minimum protective dose against lethal challenge by the clade 2.2 H5N1 virus strain A/BH Goose/QH/15C/2005 was estimated to be 5 mg/kg. This dose conferred protection against lethality in 8G9  4A7  8H5  16D7  16B12  13D4 20A11 14E4  7E2  10A8  8E2  16A4  1G6  9B3 HK483/97 0 3200 3200 400 3200 1600 3200 3200 3200 3200 400 3200 3200 3200 3200 HK486/97 0 3200 3200 3200 800 800 3200 3200 3200 3200 800 3200 3200 3200 3200
Rosybilled pochard/ HK/821/02 1 3200 3200 3200 1600 1600 3200 3200 3200 1600 3200 3200 3200 3200 3200
HK/213/03 1 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200
Dk/VNM/N-XX/04 1 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200
Ck/MYS/5858/05 1 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200
VNM/1194/04 1 3200 3200 3200 3200 3200 3200 3200 3200 1600 3200 3200 3200 3200 3200
VNM/1203/04 1 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 1600 1600
Dk/VNM/283/05 1 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200
Dk/VNM/S654/04 1 3200 1600 1600 400 Not reactive 3200 3200 3200 800 1600 3200 3200 1600 3200
Ck/Jogjakarta/BBVet-IX/04
2.1 3200 3200 3200 800 800 3200 3200 3200 3200 3200 3200 3200 3200 3200
Dk/IDN/MS/04 2.1 3200 3200 1600 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200
Ck/IDN/2A/03 2.1 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200
Ck/Bantul/BBVet1/05 2.1 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 IDN/5/05 2.1 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200
Ck/Malang/BBVet4/04 2.1 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200
Ck/Salatiga/BBVet1/05 2.1 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200
BH Goose/QH/15C/05 2.2 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200
MDk/JX/2295/05 2.2 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200
Ck/ST/4231/03 2.2 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200
Ck/HN/999/05 2.3 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200
Dk/HN/101/04 2.3 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200
Qa/GX/575/05 2.3 3200 3200 1600 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200
Ck/VNM/568/05 2.3 3200 1600 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 1600 800
Dk/HN/1265/05 2.3 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200
Dk/GX/951/05 2.3 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200
Japanese White Eye/ HK/1038/06 2.3 3200 3200 3200 1600 1600 3200 3200 3200 3200 3200 3200 1600 800 800
Dk/HN/856/05 2.3 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200
Common Magpie/HK/ 2256/06 2.3 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 SZ/406H/06 2.3 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 1600
Oriental Magpie Robin/HK/366/06 2.3 3200 3200 3200 1600 1600 3200 3200 3200 1600 3200 3200 3200 3200 3200
Dk/HN/157/05 2.3 3200 3200 3200 3200 3200 3200 3200 1600 3200 3200 3200 3200 3200 3200
Ck/GY/3570/05 2.3 3200 3200 3200 3200 3200 3200 3200 3200 Not reactive Not reactive Not reactive 3200 3200 3200
Ck/YN/115/04 2.4 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200
Gs/GX/2112/04 5 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200
Ck/GX/2439/04 5 3200 3200 1600 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200
Gs/YN/5539/05 7 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 400 Not reactive 3200 Ck/HK/YU22/02 8 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200
Ck/ST/4003/04 8 3200 3200 3200 1600 3200 3200 3200 3200 3200 3200 3200 3200 3200 3200
MDk/JX/1653/05 9 3200 3200 3200 800 800 3200 3200 3200 3200 3200 3200 3200 3200 3200
Dk/FJ/897/05 9 3200 3200 1600 1600 1600 3200 3200 3200 3200 3200 3200 3200 3200 3200 NOTE. Ascites of 52 cross-reactive H5 MAbs were titrated by HI against 41 H5N1 isolates belonging to 8 major genetic clades/subclades (0 -9), based on the H5N1 nomenclature of the World Health Organization [26] , including 4 subclades in clade 2 (clades 2.1, 2.2, 2.3, and 2.4). This table lists 14 of these MAbs. HI titers of 3200 denote high HI antibody levels, HI titers of 800 -1600 denote moderate antibody levels, HI titers of 100 -400 denote low antibody levels, and HI titers of Ͻ100 denote no reactivity. No cross-reactivity with 4 non-H5 viruses (2 H3N2 and 2 H1N1) was observed. BH Goose, bar headed goose; Ck, chicken; Dk, duck; FJ, Fujian; GD, Guangdong; Gf, guinea fowl; Gs, goose; GX, Guangxi; GY, Guanyang; HK, Hong Kong; HN, Hunan; IDN, Indonesia; JX, Jiangxi; MDk, migratory duck; MYS, Malaysia; Qa, quail; QH, Qinghai; ST, Shantou; SZ, Shenzhen; VNM, Vietnam; YN, Yunnan. all animals when it was given 1 day after virus challenge; the efficacy diminished when treatment was delayed. As doses increased, the window of opportunity for effective treatment was extended, from 2 days for a dose of 10 mg/kg to 3 days for doses of 20 mg/kg and 40 mg/kg and 4 days with a dose of 80 mg/kg. Given that untreated animals began dying 7 days after infection, the results further demonstrate that treatment with high doses of 13D4 MAb can be effective even at a relatively advanced stage of infection.
13D4 MAb binding sites. The characteristics of our broadly cross-reactive H5 MAbs strongly suggest that they may recognize 1 or more highly conserved antigenic determinants in the HA protein of H5N1 virus. To understand the molecular basis of how 13D4 recognizes proteins in antigenically diverse H5N1 vi- In the groups without monoclonal antibody (MAb) intervention, body weight change was tracked until mice died (7-10 days after infection) or had to be euthanized because of body weight loss of Ͼ30%. In the groups that received the 13D4 MAb intervention 48 h after infection, body weight change was measured until the end of the experiment (i.e., 14 days after infection). B, Virus dissemination in lung, heart, and brain was detected by immunohistochemical staining for the presence of viral nucleoprotein (brown) in tissues from mice euthanized 48 h after infection. 1, respectively, they may represent different natural immune escape mutants. Amino acid position 189, which corresponds to antigenic site B of H3N2, may represent an immunodominant epitope, and mutations at this position may thus be subject to strong positive selection [36] . As demonstrated previously [15] , A/VNM/1194/2004 contains a mutation in position 189, R189K. Its continued recognition by 13D4, together with the generation of alternate-site escape mutants observed here, suggests that 13D4 binds to multiple sites in HA, possibly preventing immune escape associated with single-site mutations.
The response of an A/VNM/1194/2004-derived escape mutant virus, N182K, to 13D4 MAb was tested in mice. As shown in figure 4, 13D4 MAb was still able to protect mice against a lethal challenge of N182K virus, although with lower efficiency than it protected wild-type mice infected with A/VNM/1194/2004, in which the MAb led to full protection, virus clearance, and rapid recouping of body weight (figures 3B and 4). Although 13D4 treatment of mice infected with the A/VNM/1194/2004 N182K escape mutant improved survival, efficiency was reduced, as evidenced by the much slower recovery of body weight (figure 4). These data further support the idea that N182K is a partial escape mutant. We suggest that the broadly protective properties of 13D4 and, possibly, of other cross-reactive MAbs may relate to their ability to bind conserved sites in the HA protein and, thus, neutralize naturally selected single-mutation H5N1 escape mutants by targeting alternate conserved sites.
DISCUSSION
Persistent endemicity of H5N1 virus in poultry, combined with continuous sporadic human transmissions, threatens to spark another influenza pandemic [37] . Antiviral agents are considered the first line of defense when initial pandemic signs emerge, regardless of their scale [2, 38] . Current anti-influenza regimens are composed mainly of neuraminidase inhibitors; their efficacy largely depends on administration before, or soon after, H5N1 virus infection [2] . Postmortem investigations of humans and of animal models of experimentally induced infection described here and in other studies reveal that H5N1 virus disseminates to multiple organs soon after infection [11, 34] , suggesting that a highly effective intervention for neutralizing virus is essential for achieving an optimal treatment outcome.
Passive immunization may provide an alternative treatment for acute infectious disease and indeed was successfully used during the 1918 pandemic and in one recent case of H5N1 influenza [8, 9] . We demonstrated in an animal model that H5-specific MAbs inhibit H5N1 virus even after infection has disseminated to multiple organs, further supporting the notion that treatment with such MAbs may be efficacious for human H5N1 infections. However, the major barrier for using such an approach to treat H5N1 infection in humans arises from the fact that avian H5N1 virus is rapidly evolving and becoming genetically and antigenically diversified over geographically broad regions [15] . Thus, to treat H5N1 infection, MAbs must accommodate the antigenic variability of circulating H5N1 variants while maintaining their capacity to neutralize. Because of the spread of antigenically distinct groups of H5N1 viruses in different regions, it can be assumed that more variants will emerge as viral evolution progresses. Ideally, then, H5 MAbs generated for prophylactic or therapeutic purposes should also be able to neutralize both currently circulating and future antigenic drift variants. We postulated that the selection of antibodies that targeted conserved epitopes in the HA protein of influenza H5N1 virus might lead to the development of broadly cross-protective antiviral MAbs.
Unlike traditional approaches, in which single viral strains were used to immunize animals, the immunization strategy adopted in this study involved repeated boosting of antibody responses to antigenic determinants common, rather than unique, to different virus isolates. We screened with a strain, A/Ck/HK/YU22/2002, isolated during the early stage of an outbreak, to facilitate the identification of MAbs that corresponded to original epitopes. The 52 broadly cross-reactive H5 MAbs obtained provide by far the most comprehensive collection of cross-reactive H5 antibodies yet generated. Although the immunizing antigens used in this study represent H5N1 strains from 2002 and subsequent years, the highly reactive pattern of the broadly cross-reactive H5 MAbs with H5N1 strains from 1997 strongly suggests that our MAb panel may also recognize epitopes preserved from original ancestral strains. Cross-protection from 2 different strains of A/VNM/1203/2004 (clade 1) and A/IDN/5/2005 (clade 2.1) was earlier described using a MAb generated from EBV-immortalized B cells obtained from patients infected with H5N1 virus [11] . Examination of other major antigenic groups of H5N1 has not been evaluated, although antigenic profile studies show that H5N1 virus has become increasing antigenically diversified during the past few years. Some variants, such as FJ-like virus (clade 2.3.4), have emerged as antigenically dominant populations in some geographical regions [14, 15] . One of our broadly cross-reactive H5 MAbs, 13D4, recognized these natural variants in neutralization assays and also protected mice from lethal challenge with 4 strains of H5N1 virus that represent major antigenic groups, including A/SZ/ 406H/2006 (an FJ-like virus). Our findings suggest that an immunization strategy involving a variety of antigenically distinct strains, as used in this study, can boost the immune response toward epitopes common or conserved among strains.
The HA protein is the most variable component of influenza virus. As a consequence of immune pressure, antigenic sites/ epitopes mutate to generate escape mutants that may give rise to influenza epidemics. Supported by the characteristics of the broadly cross-reactive MAbs described in this study, we argue that there must be some conserved antigenic epitopes/determinants in the H5N1 virus. If such epitopes are critical to virus function, they may be resistant or less susceptible to immune pressure. One of our broadly cross-reactive H5 MAbs, 13D4, targeted epitopes that appear to have been preserved since at least 1997, as outlined in table 1. The contention that our MAbs target conserved epitopes/antigenic determinants is supported by evidence that one of them, 13D4, mapped to at least 2 conserved sites, residues 152 and 182, in the HA protein. Residue 152 was described as an antigenic site in H5 HA that corresponds to site B in H3 HA in a study that used a recombinant virus Table 3 . Reactivity between 13D4-selected escape mutants and H5 monoclonal antibodies (MAbs).
containing H5N1 virus HA [36] . The antigenic properties associated with residue 182 are less clear. We showed in this study that an N182K escape mutant was partially attenuated in mice. In a previous study with a virulent H5N9 avian influenza virus, A/Turkey/Ontario/7732/1966, MAb escape mutants mapping to residues 152 and 182 were found to be attenuated, with altered cell tropism in chickens [39, 40] . It was reported that introduction of an N182K mutation enhanced ␣2,6-linked sialic acid binding activity to sialyglycopolymers containing either ␣2,3-linked or ␣2,6-linked sialic acids in A/VNM/1203/2004 but abolished its binding to both ␣2,3 or ␣2,6 sialic acids in another avian isolate [41] . Such evidence supports the idea that these sites may be critical to virus function. In support of this argument, a search of the available sequence databases identified no natural virus variants that contain mutations at both sites. We hypothesize that a virus or host mechanism may intervene to prevent survival of a natural "immune escape" mutant carrying mutations in both sites. Of note, our attempt to obtain an escape mutant carrying mutations at both sites was not successful, indirectly pointing to the possibility of potentially detrimental effects for the virus if they were doubly mutated. Thus, the properties of cross-protection of pan-H5 MAbs that we observed may lie in the fact that they target conserved, critical, and, therefore, preserved HA antigenic sites in H5N1 viruses.
We suggest that broad-spectrum MAbs such as those we have identified may ultimately, in humanized forms, prove valuable in the treatment of H5N1 infections of current and future evolving antigenic variants of H5N1 virus. Complete mapping of the HA antigenic sites recognized by these MAbs may also provide important future information relevant to H5N1 virus and its control. We postulate that our approach, and possibly even our available MAb panel, may provide tools that will aid in understanding the antigenic properties of H5N1 virus and will ultimately enhance treatment of infections in humans.
